Short oral treatment regimens for rifampicin-resistant tuberculosis are safe and effective for young children: results from a field-based, non-randomised clinical trial from Kandahar, Afghanistan

Eur Respir J. 2024 May 30;63(5):2400436. doi: 10.1183/13993003.00436-2024. Print 2024 May.

Abstract

Children have not equitably benefitted from improved RR-TB treatment shown to be efficacious in adults. This study from Afghanistan demonstrates short regimens are safe and effective in children, regardless of disease severity and resistance complexity. https://bit.ly/3UnWm43

Publication types

  • Letter
  • Clinical Trial

MeSH terms

  • Administration, Oral
  • Afghanistan
  • Antitubercular Agents* / administration & dosage
  • Antitubercular Agents* / therapeutic use
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Male
  • Mycobacterium tuberculosis / drug effects
  • Rifampin* / administration & dosage
  • Rifampin* / therapeutic use
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

  • Rifampin
  • Antitubercular Agents